Back to News
Market Impact: 0.45
Argenx To Discontinue Phase 3 UNITY Study Of Efgartigimod In Sjgren's Disease
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
argenx will discontinue the Phase 3 UNITY study of subcutaneous efgartigimod in adults with moderate-to-severe Sjögren's disease. The decision followed an interim analysis in which an Independent Data Monitoring Committee concluded the study was unable to [article text cuts off].
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately negative
Sentiment Score
-0.55
Ticker Sentiment
ARGX-0.75
More News
- Why is argenx stock rallying today?
- The world needs Ukraine’s grain. Its farmers are running out of reasons to plant
- Why is the Chinese stock market missing the AI rally
- Tesla drops 'Full Self-Driving' brand name in Europe after regulator pushback
- Why is T-Mobile stock tumbling today?
- SpaceX makes big move into wireless. These once 'obsolete' tech stocks could benefit